Xiaodong Wang sold $7.4M of ONC
director, other at BeOne Medicines Ltd.. 41,760 shares at an average of $176.50, traded Jan 7, 2025, filed Jan 8, 2025.
Score components
- +15RoleDirector
- +25Trade size$7.4M at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +25.6%, 3m +16.0%, 6m +43.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001651308-25-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 7, 2025 | MOption exercise American Depositary Shares10b5-1 | +41,760 | $6.50 | $271k | 41,760 | Jan 8, 2025 |
| Jan 7, 2025 | SOpen-market sale American Depositary Shares10b5-1 | -19,251 | $175.46 | $3.4M | 22,509 | Jan 8, 2025 |
| Jan 7, 2025 | SOpen-market sale American Depositary Shares10b5-1 | -11,310 | $176.67 | $2.0M | 11,199 | Jan 8, 2025 |
| Jan 7, 2025 | SOpen-market sale American Depositary Shares10b5-1 | -4,260 | $177.42 | $756k | 6,939 | Jan 8, 2025 |
| Jan 7, 2025 | SOpen-market sale American Depositary Shares10b5-1 | -5,638 | $178.39 | $1.0M | 1,301 | Jan 8, 2025 |
| Jan 7, 2025 | SOpen-market sale American Depositary Shares10b5-1 | -1,301 | $179.18 | $233k | 0 | Jan 8, 2025 |
| Jan 7, 2025 | MOption exercise Share Option (Right to Buy)derivative10b5-1 | -542,880 | $0.00 | $0 | 2,714,407 | Jan 8, 2025 |
Related signals
Other insiders at BeOne Medicines Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 39Weak | BeOne Medicines Ltd. | Chan Henry Lee SVP, General Counsel | $418k 1,115 shares | -100% | |
| 33Weak | BeOne Medicines Ltd. | Xiaodong Wang director, other | $11M 31,028 shares | -100% | |
| 33Weak | BeOne Medicines Ltd. | Xiaodong Wang director, other | $13M 38,287 shares | -527% | |
| 49Moderate | BeOne Medicines Ltd. | Titus B. Ball Principal Accounting Officer | $47k 132 shares | -100% | |
| 84Strong | BeOne Medicines Ltd. | John Oyler Chief Executive Officer | $934k 3,410 shares | -100% | |
| 70Notable | BeOne Medicines Ltd. | Xiaobin Wu President and COO | $357k 1,292 shares | -100% | |
| 69Notable | BeOne Medicines Ltd. | Lai Wang President, Global Head of R&D | $296k 1,068 shares | -100% | |
| 85Strong | BeOne Medicines Ltd. | John Oyler Chief Executive Officer | $981k 3,693 shares | -100% | |
| 70Notable | BeOne Medicines Ltd. | Xiaobin Wu President and COO | $362k 1,357 shares | -100% | |
| 69Notable | BeOne Medicines Ltd. | Lai Wang President, Global Head of R&D | $310k 1,169 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.